SELLAS Life Sciences (SLS) Receivables - Accured (2017)
SELLAS Life Sciences (SLS) reported Receivables - Accured of $800000.0 for Q4 2017.
SELLAS Life Sciences (SLS) Receivables - Accured (2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 1 years of Receivables - Accured data on file, last reported at $800000.0 in Q4 2017.
- Receivables - Accured for Q4 2017 came in at $800000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was $800000.0 (changed N/A YoY), and the FY2017 annual result was $800000.0, changed N/A from the prior year.
- Receivables - Accured held at $800000.0 in Q4 2017 per SLS's latest filing.
- Over five years, Receivables - Accured peaked at $800000.0 in Q4 2017 and troughed at $800000.0 in Q4 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acc. Int. Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 800,000.00 |
| Dec 31, 2017 | 800,000.00 |